ERCC1 rs11615 多态性与基于奥沙利铂的胃肠道癌症化疗临床结局的关系：一项荟萃分析。
Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis.
机构信息
Department of Oncology, The First Hospital of Lanzhou University (The Branch Hospital of Donggang), Lanzhou, Gansu Province, People's Republic of China.
Department of Gastroenterology, The First Hospital of Lanzhou University (The Branch Hospital of Donggang), Lanzhou, Gansu Province, People's Republic of China.
出版信息
Onco Targets Ther. 2015 Mar 16;8:641-8. doi: 10.2147/OTT.S80913. eCollection 2015.
PURPOSE
The relationship between the excision repair cross-complementing 1 (ERCC1) rs11615 polymorphism (C/T) and responses to oxaliplatin-based chemotherapy for gastric cancer (GC) and colorectal cancer (CRC) patients is controversial. Therefore, we performed a meta-analysis to assess this relationship.
METHOD
Relevant studies were retrieved by searching the PubMed database. A systematic review and meta-analysis was performed to evaluate the predictive value of the ERCC1 rs11615 polymorphism for the clinical outcomes of GC and CRC patients receiving oxaliplatin-based chemotherapy. Therapeutic response to chemotherapy, progression-free survival (PFS), and overall survival (OS) were analyzed.
RESULTS
A total of 22 studies were included in this meta-analysis, including 1,242 cases of GC and 1,772 cases of CRC. For the ERCC1 rs11615 polymorphism, the T allele was associated with a reduced response to chemotherapy in Asians and GC patients (P<0.05). On the other hand, the T allele was associated with a significant increase in the risk for shorter PFS and OS in all patients (PFS: hazard ratio [HR] =1.22, P<0.001, 95% confidence interval [CI] =0.93-1.51 and OS: HR =1.12, P<0.001, 95% CI =0.85-1.40).
CONCLUSION
The ERCC1 rs11615 polymorphism was closely associated with the clinical outcomes of GC and CRC patients treated with oxaliplatin-based chemotherapy.
目的
切除修复交叉互补基因 1（ERCC1）rs11615 多态性（C/T）与胃癌（GC）和结直肠癌（CRC）患者对奥沙利铂为基础的化疗反应之间的关系存在争议。因此，我们进行了一项荟萃分析来评估这种关系。
方法
通过检索 PubMed 数据库检索相关研究。系统评价和荟萃分析评估了 ERCC1 rs11615 多态性对接受奥沙利铂为基础的化疗的 GC 和 CRC 患者临床结局的预测价值。分析了化疗的治疗反应、无进展生存期（PFS）和总生存期（OS）。
结果
这项荟萃分析共纳入 22 项研究，包括 1242 例 GC 和 1772 例 CRC。对于 ERCC1 rs11615 多态性，T 等位基因与亚洲人和 GC 患者对化疗的反应降低相关（P<0.05）。另一方面，T 等位基因与所有患者的较短 PFS 和 OS 风险显著增加相关（PFS：风险比[HR] =1.22，P<0.001，95%置信区间[CI] =0.93-1.51 和 OS：HR =1.12，P<0.001，95% CI =0.85-1.40）。
结论
ERCC1 rs11615 多态性与接受奥沙利铂为基础的化疗的 GC 和 CRC 患者的临床结局密切相关。
Zotero 插件